- Wednesday, November 1, 2023
8:00 AM – 8:15 AM ET
Welcome and Introduction
8:00 AM – 8:15 AM ET
Welcome and Introduction
8:15 AM – 8:50 AM ET
Session 1: Updates in Rare Ovarian Cancers (Low Grade, Non-Serous Epithelial and Non-Epithelial)
8:15 AM – 8:50 AM ET
Session 1: Updates in Rare Ovarian Cancers (Low Grade, Non-Serous Epithelial and Non-Epithelial)Presenter: – Levine Cancer Institute at Atrium Health
Wake Forest University School of Medicine
Jubilee Brown, MD (she/her/hers) – Levine Cancer Institute at Atrium Health
Wake Forest University School of Medicine ### 1862807###Presenter###Professor and Division Director of Gynecologic Oncology###Levine Cancer Institute at Atrium Health
Wake Forest University School of Medicine###Presenter: – Levine Cancer Institute at Atrium Health
Wake Forest University School of Medicine
### she/her/hers8:50 AM – 9:00 AM ET
Live Q&A
8:50 AM – 9:00 AM ET
Live Q&AModerator: – Stephenson Cancer Center, University of Oklahoma Health Sciences Center
Presenter: – Levine Cancer Institute at Atrium Health
Wake Forest University School of Medicine
Kathleen N. Moore, MD, MS – Stephenson Cancer Center, University of Oklahoma Health Sciences Center ### 1186885###Moderator###Associate Director of Clinical Research###Stephenson Cancer Center, University of Oklahoma Health Sciences Center###Moderator: – Stephenson Cancer Center, University of Oklahoma Health Sciences Center
### @@@ Jubilee Brown, MD (she/her/hers) – Levine Cancer Institute at Atrium Health
Wake Forest University School of Medicine ### 1862807###Presenter###Professor and Division Director of Gynecologic Oncology###Levine Cancer Institute at Atrium Health
Wake Forest University School of Medicine###Presenter: – Levine Cancer Institute at Atrium Health
Wake Forest University School of Medicine
### she/her/hers9:00 AM – 9:15 AM ET
Break
9:00 AM – 9:15 AM ET
Break
9:15 AM – 10:00 AM ET
Session 2: Assessment and Intervention for Chemotherapy-Induced Neuropathy and Myopathy
9:15 AM – 10:00 AM ET
Session 2: Assessment and Intervention for Chemotherapy-Induced Neuropathy and MyopathyPresenter: – The University of Oklahoma Health Sciences Center/ OU Health Stephenson Cancer Center
Elizabeth Hile, PT, PhD (she/her/hers) – The University of Oklahoma Health Sciences Center/ OU Health Stephenson Cancer Center ### 1862413###Presenter###Associate Professor/ Director of Cancer Rehabilitation Research & Laboratory###The University of Oklahoma Health Sciences Center/ OU Health Stephenson Cancer Center###Presenter: – The University of Oklahoma Health Sciences Center/ OU Health Stephenson Cancer Center
### she/her/hers10:00 AM – 10:15 AM ET
Break
10:00 AM – 10:15 AM ET
Break
10:15 AM – 11:15 AM ET
Non-CME Innovation Theater
10:15 AM – 11:15 AM ET
Non-CME Innovation Theater
11:15 AM – 11:30 AM ET
Break
11:15 AM – 11:30 AM ET
Break
11:30 AM – 12:05 PM ET
Session 3: Management and Challenges of Cervical Cancer Treatment in the Second Line and Beyond
11:30 AM – 12:05 PM ET
Session 3: Management and Challenges of Cervical Cancer Treatment in the Second Line and BeyondPresenter: – Stephenson Cancer Center, University of Oklahoma Health Sciences Center
Debra Richardson, MD (she/her/hers) – Stephenson Cancer Center, University of Oklahoma Health Sciences Center ### 1186893###Presenter###Associate Professor###Stephenson Cancer Center, University of Oklahoma Health Sciences Center###Presenter: – Stephenson Cancer Center, University of Oklahoma Health Sciences Center
### she/her/hers12:05 PM – 12:15 PM ET
Live Q&A
12:05 PM – 12:15 PM ET
Live Q&AModerator: – Stephenson Cancer Center, University of Oklahoma Health Sciences Center
Presenter: – Stephenson Cancer Center, University of Oklahoma Health Sciences Center
Kathleen N. Moore, MD, MS – Stephenson Cancer Center, University of Oklahoma Health Sciences Center ### 1186885###Moderator###Associate Director of Clinical Research###Stephenson Cancer Center, University of Oklahoma Health Sciences Center###Moderator: – Stephenson Cancer Center, University of Oklahoma Health Sciences Center
### @@@ Debra Richardson, MD (she/her/hers) – Stephenson Cancer Center, University of Oklahoma Health Sciences Center ### 1186893###Presenter###Associate Professor###Stephenson Cancer Center, University of Oklahoma Health Sciences Center###Presenter: – Stephenson Cancer Center, University of Oklahoma Health Sciences Center
### she/her/hers12:15 PM – 12:30 PM ET
Break
12:15 PM – 12:30 PM ET
Break
12:30 PM – 1:15 PM ET
Session 4: Endometrial Cancer Treatment Debate: Checkpoint Inhibitors for All vs Individualized Therapies Beyond Checkpoint Inhibitors
12:30 PM – 12:45 PM ET
Session 4: Checkpoint Inhibitors for AllPresenter: – University of California, San Diego
Ramez Eskander, MD – University of California, San Diego ### 1416358###Presenter###Associate Professor###University of California, San Diego###Presenter: – University of California, San Diego
### 12:45 PM – 1:00 PM ET
Session 4: Individualized Checkpoint InhibitorsPresenter: – Director, Principal Investigator, Community Research Development, HonorHealth Research Institute
Bradley Monk, MD – Director, Principal Investigator, Community Research Development, HonorHealth Research Institute ### 1186886###Presenter###Gynecologic Oncologist###Director, Principal Investigator, Community Research Development, HonorHealth Research Institute###Presenter: – Director, Principal Investigator, Community Research Development, HonorHealth Research Institute
### 1:00 PM – 1:15 PM ET
Live Panel DiscussionModerator: – Stephenson Cancer Center, University of Oklahoma Health Sciences Center
Presenter: – Director, Principal Investigator, Community Research Development, HonorHealth Research Institute
Presenter: – University of California, San Diego
Kathleen N. Moore, MD, MS – Stephenson Cancer Center, University of Oklahoma Health Sciences Center ### 1186885###Moderator###Associate Director of Clinical Research###Stephenson Cancer Center, University of Oklahoma Health Sciences Center###Moderator: – Stephenson Cancer Center, University of Oklahoma Health Sciences Center
### @@@ Bradley Monk, MD – Director, Principal Investigator, Community Research Development, HonorHealth Research Institute ### 1186886###Presenter###Gynecologic Oncologist###Director, Principal Investigator, Community Research Development, HonorHealth Research Institute###Presenter: – Director, Principal Investigator, Community Research Development, HonorHealth Research Institute
### @@@ Ramez Eskander, MD – University of California, San Diego ### 1416358###Presenter###Associate Professor###University of California, San Diego###Presenter: – University of California, San Diego
### 1:15 PM – 1:30 PM ET
Break
1:15 PM – 1:30 PM ET
Break
1:30 PM – 2:30 PM ET
Non-CME Innovation Theater
1:30 PM – 2:30 PM ET
Non-CME Innovation Theater
2:30 PM – 2:45 PM ET
Break
2:30 PM – 2:45 PM ET
Break
2:45 PM – 3:20 PM ET
Session 5: Updates in Front Line Adjuvant and Metastatic Treatment of Endometrial Cancer
2:45 PM – 3:20 PM ET
Session 5: Updates in Front Line Adjuvant and Metastatic Treatment of Endometrial Cancer
Matthew Powell, MD (he/him/his) – Washington University School of Medicine ### 1929977###Invited Speaker###Professor and Chief Division Gynecologic Oncology###Washington University School of Medicine###Invited Speaker: – Washington University School of Medicine
### he/him/his3:20 PM – 3:30 PM ET
Live Q&A
3:20 PM – 3:30 PM ET
Live Q&AModerator: – Stephenson Cancer Center, University of Oklahoma Health Sciences Center
Kathleen N. Moore, MD, MS – Stephenson Cancer Center, University of Oklahoma Health Sciences Center ### 1186885###Moderator###Associate Director of Clinical Research###Stephenson Cancer Center, University of Oklahoma Health Sciences Center###Moderator: – Stephenson Cancer Center, University of Oklahoma Health Sciences Center
### @@@ Matthew Powell, MD (he/him/his) – Washington University School of Medicine ### 1929977###Invited Speaker###Professor and Chief Division Gynecologic Oncology###Washington University School of Medicine###Invited Speaker: – Washington University School of Medicine
### he/him/his3:30 PM – 3:45 PM ET
Break
3:30 PM – 3:45 PM ET
Break
3:45 PM – 4:20 PM ET
Session 6: Emerging Developments in Recurrent (2L and beyond) Endometrial Cancer
3:45 PM – 4:20 PM ET
Session 6: Emerging Developments in Recurrent (2L and beyond) Endometrial CancerPresenter: – Stephenson Cancer Center, University of Oklahoma Health Sciences Center
Kathleen N. Moore, MD, MS – Stephenson Cancer Center, University of Oklahoma Health Sciences Center ### 1186885###Presenter###Associate Director of Clinical Research###Stephenson Cancer Center, University of Oklahoma Health Sciences Center###Presenter: – Stephenson Cancer Center, University of Oklahoma Health Sciences Center
### 4:20 PM – 4:30 PM ET
Live Q&A
4:20 PM – 4:30 PM ET
Live Q&A
4:30 PM – 4:45 PM ET
Break
4:30 PM – 4:45 PM ET
Break
4:45 PM – 5:20 PM ET
Session 7: Updates in Molecular Testing and Front-Line Treatment in Ovarian Cancer
4:45 PM – 5:20 PM ET
Session 7: Updates in Molecular Testing and Front-Line Treatment in Ovarian CancerPresenter: – Director, Principal Investigator, Community Research Development, HonorHealth Research Institute
Bradley Monk, MD – Director, Principal Investigator, Community Research Development, HonorHealth Research Institute ### 1186886###Presenter###Gynecologic Oncologist###Director, Principal Investigator, Community Research Development, HonorHealth Research Institute###Presenter: – Director, Principal Investigator, Community Research Development, HonorHealth Research Institute
### 5:20 PM – 5:30 PM ET
Live Q&A
5:20 PM – 5:30 PM ET
Live Q&AModerator: – Stephenson Cancer Center, University of Oklahoma Health Sciences Center
Presenter: – Director, Principal Investigator, Community Research Development, HonorHealth Research Institute
Kathleen N. Moore, MD, MS – Stephenson Cancer Center, University of Oklahoma Health Sciences Center ### 1186885###Moderator###Associate Director of Clinical Research###Stephenson Cancer Center, University of Oklahoma Health Sciences Center###Moderator: – Stephenson Cancer Center, University of Oklahoma Health Sciences Center
### @@@ Bradley Monk, MD – Director, Principal Investigator, Community Research Development, HonorHealth Research Institute ### 1186886###Presenter###Gynecologic Oncologist###Director, Principal Investigator, Community Research Development, HonorHealth Research Institute###Presenter: – Director, Principal Investigator, Community Research Development, HonorHealth Research Institute
### - Thursday, November 2, 2023
8:00 AM – 8:15 AM ET
Welcome and Introduction
8:00 AM – 8:15 AM ET
Welcome and Introduction
8:15 AM – 8:50 AM ET
Session 8: Advanced Ovarian Cancer Therapies: PARP Inhibitors and Beyond
8:15 AM – 8:50 AM ET
Session 8: Advanced Ovarian Cancer Therapies: PARP Inhibitors and Beyond
Debra Richardson, MD (she/her/hers) – Stephenson Cancer Center, University of Oklahoma Health Sciences Center ### 1186893###Invited Speaker###Associate Professor###Stephenson Cancer Center, University of Oklahoma Health Sciences Center###Invited Speaker: – Stephenson Cancer Center, University of Oklahoma Health Sciences Center
### she/her/hers8:50 AM – 9:00 AM ET
Live Q&A
8:50 AM – 9:00 AM ET
Live Q&AModerator: – Stephenson Cancer Center, University of Oklahoma Health Sciences Center
Kathleen N. Moore, MD, MS – Stephenson Cancer Center, University of Oklahoma Health Sciences Center ### 1186885###Moderator###Associate Director of Clinical Research###Stephenson Cancer Center, University of Oklahoma Health Sciences Center###Moderator: – Stephenson Cancer Center, University of Oklahoma Health Sciences Center
### @@@ Debra Richardson, MD (she/her/hers) – Stephenson Cancer Center, University of Oklahoma Health Sciences Center ### 1186893###Invited Speaker###Associate Professor###Stephenson Cancer Center, University of Oklahoma Health Sciences Center###Invited Speaker: – Stephenson Cancer Center, University of Oklahoma Health Sciences Center
### she/her/hers9:00 AM – 9:15 AM ET
Break
9:00 AM – 9:15 AM ET
Break
9:15 AM – 9:50 AM ET
Session 9: Relapsing Ovarian Cancer: Expert Advice for Selecting New and Emerging Targeted Therapeutics
9:15 AM – 9:50 AM ET
Session 9: Relapsing Ovarian Cancer: Expert Advice for Selecting New and Emerging Targeted TherapeuticsPresenter: – University of New Mexico Cancer Center
Colleen McCormick, MD, MPH (she/her/hers) – University of New Mexico Cancer Center ### 1953572###Presenter###Associate Professor, Gynecologic Oncology###University of New Mexico Cancer Center###Presenter: – University of New Mexico Cancer Center
### she/her/hers9:50 AM – 10:00 AM ET
Live Q&A
9:50 AM – 10:00 AM ET
Live Q&AModerator: – Stephenson Cancer Center, University of Oklahoma Health Sciences Center
Presenter: – University of New Mexico Cancer Center
Kathleen N. Moore, MD, MS – Stephenson Cancer Center, University of Oklahoma Health Sciences Center ### 1186885###Moderator###Associate Director of Clinical Research###Stephenson Cancer Center, University of Oklahoma Health Sciences Center###Moderator: – Stephenson Cancer Center, University of Oklahoma Health Sciences Center
### @@@ Colleen McCormick, MD, MPH (she/her/hers) – University of New Mexico Cancer Center ### 1953572###Presenter###Associate Professor, Gynecologic Oncology###University of New Mexico Cancer Center###Presenter: – University of New Mexico Cancer Center
### she/her/hers10:00 AM – 10:15 AM ET
Break
10:00 AM – 10:15 AM ET
Break
10:15 AM – 11:15 AM ET
Non-CME Innovation Theater
10:15 AM – 11:15 AM ET
Non-CME Innovation Theater
11:15 AM – 11:30 AM ET
Break
11:15 AM – 11:30 AM ET
Break
11:30 AM – 12:05 PM ET
Session 10: Food Insecurity in Oncology
11:30 AM – 12:05 PM ET
Session 10: Food Insecurity in OncologyPresenter: – University of Oklahoma
Christina Washington, MD (she/her/hers) – University of Oklahoma ### 1862808###Presenter###Assistant Professor### University of Oklahoma###Presenter: – University of Oklahoma
### she/her/hers12:05 PM – 12:15 PM ET
Live Q&A
12:05 PM – 12:15 PM ET
Live Q&AModerator: – Stephenson Cancer Center, University of Oklahoma Health Sciences Center
Presenter: – University of Oklahoma
Kathleen N. Moore, MD, MS – Stephenson Cancer Center, University of Oklahoma Health Sciences Center ### 1186885###Moderator###Associate Director of Clinical Research###Stephenson Cancer Center, University of Oklahoma Health Sciences Center###Moderator: – Stephenson Cancer Center, University of Oklahoma Health Sciences Center
### @@@ Christina Washington, MD (she/her/hers) – University of Oklahoma ### 1862808###Presenter###Assistant Professor### University of Oklahoma###Presenter: – University of Oklahoma
### she/her/hers12:15 PM – 12:30 PM ET
Break
12:15 PM – 12:30 PM ET
Break
12:30 PM – 1:05 PM ET
Session 11: Updates from Recent Meetings
12:30 PM – 1:05 PM ET
Session 11: Updates from Recent MeetingsPresenter: – University of California, San Diego
Ramez Eskander, MD – University of California, San Diego ### 1416358###Presenter###Associate Professor###University of California, San Diego###Presenter: – University of California, San Diego
### 1:05 PM – 1:15 PM ET
Live Q&A
1:05 PM – 1:15 PM ET
Live Q&APresenter: – University of California, San Diego
Ramez Eskander, MD – University of California, San Diego ### 1416358###Presenter###Associate Professor###University of California, San Diego###Presenter: – University of California, San Diego
### 1:15 PM – 1:30 PM ET
Break
1:15 PM – 1:30 PM ET
Break
1:30 PM – 2:30 PM ET
Non-CME Innovation Theater
1:30 PM – 2:30 PM ET
Non-CME Innovation Theater
2:30 PM – 2:45 PM ET
Break
2:30 PM – 2:45 PM ET
Break
2:45 PM – 3:20 PM ET
Session 12: Collateral Damage: Side Effects of Breast Cancer Treatment
2:45 PM – 3:20 PM ET
Session 12: Collateral Damage: Side Effects of Breast Cancer TreatmentPresenter: – Texas Oncology -Baylor Charles A. Sammons Cancer Center
Marissa Marti-Smith, MSN, APRN, AGNP-C, AOCNP – Texas Oncology -Baylor Charles A. Sammons Cancer Center ### 1897031###Presenter###Nurse Practitioner###Texas Oncology -Baylor Charles A. Sammons Cancer Center###Presenter: – Texas Oncology -Baylor Charles A. Sammons Cancer Center
### 3:20 PM – 3:30 PM ET
Live Q&A
3:20 PM – 3:30 PM ET
Live Q&AModerator: – Sarah Cannon Research Institute (SCRI)
Presenter: – Texas Oncology -Baylor Charles A. Sammons Cancer Center
Erika P. Hamilton, MD – Sarah Cannon Research Institute (SCRI) ### 1186741###Moderator###Director, Breast and Gynecologic Cancer Research Program###Sarah Cannon Research Institute (SCRI)###Moderator: – Sarah Cannon Research Institute (SCRI)
### @@@ Marissa Marti-Smith, MSN, APRN, AGNP-C, AOCNP – Texas Oncology -Baylor Charles A. Sammons Cancer Center ### 1897031###Presenter###Nurse Practitioner###Texas Oncology -Baylor Charles A. Sammons Cancer Center###Presenter: – Texas Oncology -Baylor Charles A. Sammons Cancer Center
### 3:30 PM – 3:45 PM ET
Break
3:30 PM – 3:45 PM ET
Break
3:45 PM – 4:30 PM ET
Session 13: Debate: Should We Quantify HER-2 Expression for Use of TDXd and Other ADCs?
3:45 PM – 4:00 PM ET
Session 13: Debate: Should We Quantify HER-2 Expression for Use of TDXd and Other ADCs? - YESPresenter: – European Insitute of Oncology, IRCCS and University of Milano
Giuseppe Curigliano, Professor MD PhD (he/him/his) – European Insitute of Oncology, IRCCS and University of Milano ### 1867030###Presenter###Clinical Director Early Drug Development Division###European Insitute of Oncology, IRCCS and University of Milano###Presenter: – European Insitute of Oncology, IRCCS and University of Milano
### he/him/his4:00 PM – 4:15 PM ET
Session 13: Debate: Should We Quantify HER-2 Expression for Use of TDXd and Other ADCs? - NOPresenter: – Dana-Farber Cancer Institute, Harvard Medical School
Paolo Tarantino, MD (he/him/his) – Dana-Farber Cancer Institute, Harvard Medical School ### 1928334###Presenter###Advanced Research Fellow###Dana-Farber Cancer Institute, Harvard Medical School###Presenter: – Dana-Farber Cancer Institute, Harvard Medical School
### he/him/his4:15 PM – 4:30 PM ET
Live Panel DiscussionModerator: – Sarah Cannon Research Institute (SCRI)
Panelist: – European Insitute of Oncology, IRCCS and University of Milano
Panelist: – Dana-Farber Cancer Institute, Harvard Medical School
Erika P. Hamilton, MD – Sarah Cannon Research Institute (SCRI) ### 1186741###Moderator###Director, Breast and Gynecologic Cancer Research Program###Sarah Cannon Research Institute (SCRI)###Moderator: – Sarah Cannon Research Institute (SCRI)
### @@@ Giuseppe Curigliano, Professor MD PhD (he/him/his) – European Insitute of Oncology, IRCCS and University of Milano ### 1867030###Panelist###Clinical Director Early Drug Development Division###European Insitute of Oncology, IRCCS and University of Milano###Panelist: – European Insitute of Oncology, IRCCS and University of Milano
### he/him/his @@@ Paolo Tarantino, MD (he/him/his) – Dana-Farber Cancer Institute, Harvard Medical School ### 1928334###Panelist###Advanced Research Fellow###Dana-Farber Cancer Institute, Harvard Medical School###Panelist: – Dana-Farber Cancer Institute, Harvard Medical School
### he/him/his4:30 PM – 4:45 PM ET
Break
4:30 PM – 4:45 PM ET
Break
4:45 PM – 5:20 PM ET
Session 14: CDK4/6 Inhibitors Results in Early and Metastatic Breast Cancer
4:45 PM – 5:20 PM ET
Session 14: CDK4/6 Inhibitors Results in Early and Metastatic Breast CancerPresenter: – Memorial Sloan Kettering Cancer Center
Komal Jhaveri, MD, FACP – Memorial Sloan Kettering Cancer Center ### 1416347###Presenter###Medical Oncologist and Clinical Researcher, Breast Medicine and Early Drug Development###Memorial Sloan Kettering Cancer Center###Presenter: – Memorial Sloan Kettering Cancer Center
### 5:20 PM – 5:30 PM ET
Live Q&A
5:20 PM – 5:30 PM ET
Live Q&APresenter: – Memorial Sloan Kettering Cancer Center
Komal Jhaveri, MD, FACP – Memorial Sloan Kettering Cancer Center ### 1416347###Presenter###Medical Oncologist and Clinical Researcher, Breast Medicine and Early Drug Development###Memorial Sloan Kettering Cancer Center###Presenter: – Memorial Sloan Kettering Cancer Center
### - Friday, November 3, 2023
8:00 AM – 8:15 AM ET
Welcome and Introduction
8:00 AM – 8:15 AM ET
Welcome and Introduction
8:15 AM – 8:50 AM ET
Session 15: Special Topics in HR+ Breast Cancer
8:15 AM – 8:50 AM ET
Session 15: Special Topics in HR+ Breast CancerPresenter: – Winship Cancer Institute at Emory University
Kevin Kalinsky, MD, MS (he/him/his) – Winship Cancer Institute at Emory University ### 1538154###Presenter###Director, Glenn Family Breast Center###Winship Cancer Institute at Emory University###Presenter: – Winship Cancer Institute at Emory University
### he/him/his8:50 AM – 9:00 AM ET
Live Q&A
8:50 AM – 9:00 AM ET
Live Q&APresenter: – Winship Cancer Institute at Emory University
Kevin Kalinsky, MD, MS (he/him/his) – Winship Cancer Institute at Emory University ### 1538154###Presenter###Director, Glenn Family Breast Center###Winship Cancer Institute at Emory University###Presenter: – Winship Cancer Institute at Emory University
### he/him/his9:00 AM – 9:15 AM ET
Break
9:00 AM – 9:15 AM ET
Break
9:15 AM – 10:00 AM ET
Session 16: ER-Positive Targeted Therapy: PI3, AKT, mTOR, etc
9:15 AM – 10:00 AM ET
Session 16: ER-Positive Targeted Therapy: PI3, AKT, mTOR, etcPresenter: – Baylor Charles A. Sammons Cancer Center/ Baylor University Medical Center/ Texas Oncology
Joyce O'Shaughnessy, MD – Baylor Charles A. Sammons Cancer Center/ Baylor University Medical Center/ Texas Oncology ### 1879169###Presenter###Medical Oncologist###Baylor Charles A. Sammons Cancer Center/ Baylor University Medical Center/ Texas Oncology###Presenter: – Baylor Charles A. Sammons Cancer Center/ Baylor University Medical Center/ Texas Oncology
### 10:00 AM – 10:15 AM ET
Break
10:00 AM – 10:15 AM ET
Break
10:15 AM – 11:15 AM ET
Non-CME Innovation Theater
10:15 AM – 11:15 AM ET
Non-CME Innovation Theater
11:15 AM – 11:30 AM ET
Break
11:15 AM – 11:30 AM ET
Break
11:30 AM – 12:05 PM ET
Session 17: HER2-Positive Metastatic Breast Cancer: Where are We Headed?
11:30 AM – 12:05 PM ET
Session 17: HER2-Positive Metastatic Breast Cancer: Where are We Headed?Presenter: – University of California, Los Angeles
Sara Hurvitz, MD – University of California, Los Angeles ### 1186881###Presenter###Professor of Medicine###University of California, Los Angeles###Presenter: – University of California, Los Angeles
### 11:30 AM – 12:15 PM ET
Session 17: HER2-Positive Metastatic Breast Cancer: Where are We Headed?
12:05 PM – 12:15 PM ET
Live Q&AModerator: – Sarah Cannon Research Institute (SCRI)
Presenter: – University of California, Los Angeles
Erika P. Hamilton, MD – Sarah Cannon Research Institute (SCRI) ### 1186741###Moderator###Director, Breast and Gynecologic Cancer Research Program###Sarah Cannon Research Institute (SCRI)###Moderator: – Sarah Cannon Research Institute (SCRI)
### @@@ Sara Hurvitz, MD – University of California, Los Angeles ### 1186881###Presenter###Professor of Medicine###University of California, Los Angeles###Presenter: – University of California, Los Angeles
### 12:15 PM – 12:30 PM ET
Break
12:15 PM – 12:30 PM ET
Break
12:30 PM – 1:05 PM ET
Session 18: Immunotherapy for Breast Cancer
12:30 PM – 1:05 PM ET
Session 18: Immunotherapy for Breast CancerPresenter: – International Breast Cancer Center , IBCC
Javier Cortes, MD, PhD – International Breast Cancer Center , IBCC ### 1186877###Presenter###Head###International Breast Cancer Center , IBCC###Presenter: – International Breast Cancer Center , IBCC
### 1:05 PM – 1:15 PM ET
Live Q&A
1:05 PM – 1:15 PM ET
Live Q&AModerator: – Sarah Cannon Research Institute (SCRI)
Presenter: – International Breast Cancer Center , IBCC
Erika P. Hamilton, MD – Sarah Cannon Research Institute (SCRI) ### 1186741###Moderator###Director, Breast and Gynecologic Cancer Research Program###Sarah Cannon Research Institute (SCRI)###Moderator: – Sarah Cannon Research Institute (SCRI)
### @@@ Javier Cortes, MD, PhD – International Breast Cancer Center , IBCC ### 1186877###Presenter###Head###International Breast Cancer Center , IBCC###Presenter: – International Breast Cancer Center , IBCC
### 1:15 PM – 1:30 PM ET
Break
1:15 PM – 1:30 PM ET
Break
1:30 PM – 2:05 PM ET
Session 19: PARP Inhibitors and Beyond in Breast Cancer Treatment
1:30 PM – 2:05 PM ET
Session 19: PARP Inhibitors and Beyond in Breast Cancer Treatment
Hope S. Rugo, MD, FASCO – Helen Diller Family Comprehensive Cancer Center; University of California, San Francisco ### 1186884###Invited Speaker###Professor of Medicine; Director, Breast Oncology and Clinical Trials Education###Helen Diller Family Comprehensive Cancer Center; University of California, San Francisco###Invited Speaker: – Helen Diller Family Comprehensive Cancer Center; University of California, San Francisco
### @@@ Joyce O'Shaughnessy, MD – Baylor Charles A. Sammons Cancer Center/ Baylor University Medical Center/ Texas Oncology ### 1879169###Invited Speaker###Medical Oncologist###Baylor Charles A. Sammons Cancer Center/ Baylor University Medical Center/ Texas Oncology###Invited Speaker: – Baylor Charles A. Sammons Cancer Center/ Baylor University Medical Center/ Texas Oncology
### 2:05 PM – 2:15 PM ET
Live Q&A
2:05 PM – 2:15 PM ET
Live Q&AModerator: – Sarah Cannon Research Institute (SCRI)
Erika P. Hamilton, MD – Sarah Cannon Research Institute (SCRI) ### 1186741###Moderator###Director, Breast and Gynecologic Cancer Research Program###Sarah Cannon Research Institute (SCRI)###Moderator: – Sarah Cannon Research Institute (SCRI)
### @@@ Tiffany Traina ### 2144178###Invited Speaker#########Invited Speaker:
### 2:15 PM – 2:30 PM ET
Break
2:15 PM – 2:30 PM ET
Break
2:30 PM – 3:15 PM ET
Session 20: Novel Endocrine Backbones
2:30 PM – 3:15 PM ET
Session 20: Novel Endocrine BackbonesPresenter: – Sarah Cannon Research Institute (SCRI)
Erika P. Hamilton, MD – Sarah Cannon Research Institute (SCRI) ### 1186741###Presenter###Director, Breast and Gynecologic Cancer Research Program###Sarah Cannon Research Institute (SCRI)###Presenter: – Sarah Cannon Research Institute (SCRI)
### 3:15 PM – 3:30 PM ET
Break
3:15 PM – 3:30 PM ET
Break
3:30 PM – 4:05 PM ET
Session 21: HER2-Low Breast Cancer: Limits of Testing and Where To Go From Here
3:30 PM – 4:05 PM ET
Session 21: HER2-Low Breast Cancer: Limits of Testing and Where To Go From HerePresenter: – Dana-Farber Cancer Institute, Harvard Medical School
Paolo Tarantino, MD (he/him/his) – Dana-Farber Cancer Institute, Harvard Medical School ### 1928334###Presenter###Advanced Research Fellow###Dana-Farber Cancer Institute, Harvard Medical School###Presenter: – Dana-Farber Cancer Institute, Harvard Medical School
### he/him/his4:05 PM – 4:15 PM ET
Live Q&A
4:05 PM – 4:15 PM ET
Live Q&AModerator: – Sarah Cannon Research Institute (SCRI)
Presenter: – Dana-Farber Cancer Institute, Harvard Medical School
Erika P. Hamilton, MD – Sarah Cannon Research Institute (SCRI) ### 1186741###Moderator###Director, Breast and Gynecologic Cancer Research Program###Sarah Cannon Research Institute (SCRI)###Moderator: – Sarah Cannon Research Institute (SCRI)
### @@@ Paolo Tarantino, MD (he/him/his) – Dana-Farber Cancer Institute, Harvard Medical School ### 1928334###Presenter###Advanced Research Fellow###Dana-Farber Cancer Institute, Harvard Medical School###Presenter: – Dana-Farber Cancer Institute, Harvard Medical School
### he/him/his
